Should I Buy OLMA? OLMA 2026 Analysis

Should You Buy Olema Pharmaceuticals Inc (OLMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

26.060

1 Day change

6.06%

52 Week Range

36.260

Analysis Updated At

2026/01/26

Olema Pharmaceuticals Inc (OLMA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the recent price decline, the stock has strong positive catalysts, favorable analyst ratings, and a promising long-term growth outlook in the biotech space. The lack of significant insider or hedge fund activity and the absence of recent political trading do not detract from the investment opportunity.

Technical Analysis

The MACD is negatively expanding, indicating a bearish trend. RSI is at 31.415, nearing oversold territory but still neutral. Moving averages are converging, suggesting indecision in the market. Key support is at 25.67, and resistance is at 29.031. The stock is trading near its support level, which could present a buying opportunity for long-term investors.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low open interest put-call ratio indicates bullish sentiment, while the high option volume put-call ratio suggests significant put activity, possibly due to short-term hedging or bearish sentiment. Overall, options data is mixed but leans slightly positive for long-term investors.

Technical Summary

Sell

Buy

Positive Catalysts

Strong analyst ratings with multiple Buy and Overweight recommendations from UBS, Piper Sandler, Citi, Oppenheimer, Goldman Sachs, and Jefferies. Price targets range from $38 to $60, significantly above the current price.
Positive read-through from Roche's Phase 3 lidERA trial results, which validate Olema's palazestrant potential.
Upcoming Phase 3 data in the second half of 2026 for Olema's palazestrant, which could be a major growth driver.

Neutral/Negative Catalysts

Recent price decline of -4.50% in regular trading and -0.12% post-market, which may indicate short-term bearish sentiment.
Financial performance shows no revenue and a net loss of -$42.2M in Q3 2025, though the loss improved YoY.
High implied volatility (182.06) and historical volatility (263.48) indicate significant risk and uncertainty.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$42.2M, which improved by 22.17% YoY. EPS dropped by -18.33% YoY to -0.49. While the company is not yet profitable, the improvement in net income suggests better cost management.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on OLMA, with multiple Buy and Overweight ratings. Price targets range from $38 to $60, indicating significant upside potential. Analysts highlight the company's promising drug pipeline, particularly palazestrant, and the positive impact of Roche's lidERA trial results on Olema's outlook.

11 Analyst Rating

Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42 USD with a low forecast of 20 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.570

Low

Averages

High

Current: 24.570

Low

Averages

High

UBS

Buy

initiated

$45

AI Analysis

2026-01-07

Reason

UBS

Price Target

$45

AI Analysis

2026-01-07

initiated

Buy

Reason

UBS initiated coverage of Olema Oncology (OLMA) with a Buy rating and $45 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Piper Sandler

Overweight

initiated

$40

2026-01-07

Reason

Piper Sandler

Price Target

$40

2026-01-07

initiated

Overweight

Reason

Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OLMA

Unlock Now

OLMA Should I Buy

OLMA Should I Buy

Should You Buy Olema Pharmaceuticals Inc (OLMA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch